Peptide research · 2026
The peptide era of metabolic research
From GLP-1 to triple agonists, peptides have become the most active frontier in metabolic science. Here's where the research stands, and where labs source tested compounds.
3
Generations of incretin research: GLP-1, dual, triple
24%
Mean body-weight reduction at 48 weeks in the Phase 2 retatrutide trial (NEJM, 2023)
100+
Peptide therapeutics approved worldwide, with hundreds more in trials
The emerging market
Four shifts driving peptide research
Multi-receptor design
Research has moved from single-target peptides to molecules engaging two or three metabolic receptors at once.
Rapid market growth
Metabolic peptides are among the fastest-growing areas in pharmaceutical R&D, drawing major investment.
Lab demand rising
Independent labs increasingly study these compounds, which puts purity and verified sourcing first.
Testing is the standard
Third-party HPLC and mass-spec certificates are now the minimum expectation for research material.
Featured compound
GLP-3R (Retatrutide)
The triple agonist acting on GLP-1, GIP and glucagon receptors, with the strongest weight-reduction results reported in its class so far.
Source tested research peptides
Every Purple Peptides batch ships with a Certificate of Analysis.